Abbvie (ABBV) exec says there will be some erosion from Imbruvica due to competition and price negotiation, via JPM Conference

AbbVie executives indicating potential erosion of Imbruvica's market position due to rising competition and ongoing price negotiations signals a challenging outlook for this key product.

Newsquawk StaffPublished On the live feed at 10 more headlines followed before this page went public
Newsquawk headlinesUTC

Oracle (ORCL) is being sued by bondholders who were hit with losses as the co. did not disclose it needed to sell significant additional debt to build AI infrastructure

US Treasury Secretary Bessent met with Australian Treasurer to discuss critical minerals opportunities, as well as mutual concerns of economic and national security interest

Abbvie (ABBV) exec says there will be some erosion from Imbruvica due to competition and price negotiation, via JPM Conference

Paramount (PSKY) and Netflix (NFLX) met with the European Commission on Tuesday, according to Semafor

CNB Vice Governor Zamrazilova says services inflation is preventing more rate cuts, via radio interview

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This could impact AbbVie's revenue projections and overall earnings, especially in comparison to peers in the biotechnology sector contend with similar pressures. Traders should closely watch how this affects AbbVie's stock performance and broader market sentiment towards its pharmaceuticals.

Related headlines

The whole workspace, free to try.

Try it free